Aim: Selective serotonin reuptake inhibitors (SSRIs) are one of the most common antidepressant drugs. SSRI use is associated with increased risk of bone fracture and titanium implant failure. The aim of this in vivo study was to investigate the effect of SSRIs on osseointegration and bone healing. Materials and Methods: On a total of 24 Sprague-Dawley rats, a custom-made titanium implant was placed in the left tibia, while a unicortical defect was created in the right tibia. Rats were assigned randomly into two groups and received a daily dose of either sertraline (5 mg/kg) or saline. After two weeks, they were euthanized and bone healing and osseointegration were assessed by micro-CT and histology. Results: Bone formation in bone defects was significantly lower (p < 0.05) in sertraline-treated rats (BV/TV = 20.67 ± 11.98%) compared to the controls (BV/TV = 37.87 ± 9.56%). Furthermore, the percentage of osseointegration was significantly lower (p < 0.05) in sertraline-treated rats (34.40 ± 7.17%) compared to the controls (54.37 ± 8.58%). Conclusion: Sertraline hinders bone healing and implant osseointegration.
Bibliographical noteFunding Information:
Natural Sciences and Engineering Research Council of Canada NSERC-Discovery; International Team for Implantology ITI, Grant/Award Number: 1118_2015; Canadian Foundation for Innovation; Fonds de recherche du Québec – Nature et technologies FRQNT
This work was supported by an operating grant from International Team for Implantology (ITI) fund no.1118_2015 to (F.Tamimi). The Fonds de recherche du Québec – Nature et technologies (FRQNT; MN.Abdallah), Canadian Foundation for Innovation (CFI, F. Tamimi), Natural Sciences and Engineering Research Council of Canada NSERC-Discovery (F. Tamimi), Canada Research Chair (F. Tamimi).
- bone healing
- selective serotonin reuptake inhibitors